France 2nd in the world?
Enlarge image


France 2nd in the world?

24.05.2012 - France Biotech has presented its 2011 biotech survey together with France Biotech. The results are very favorable for the country.

Paris – The data of the Life Science Panorama 2010/11 survey provided by Ernst & Young claim a leading role for French biotechnology in the world. The accounting specialist has found an impressive number of 1,359 life science companies that are active in France, ranking the country 2nd in the world in terms of the number of such companies. However, the survey gives no clear criteria for the selection of the firms included. Other studies use clearly defined and internationally comparable criteria defined by the OECD. Furthermore, Ernst & Young only surveyed only about 200 companies. 103 firms responded. On this basis, Ernst & Young calculated annual revenues of €261 million in France. In comparison, a report from conform to OECD criteria found 552 biotech companies in Germany with €2.4bn in sales. As in Europe, the amount of private equity available for biotechs dropped sharply in France between 2010 and 2011 from €460m to €277m according to Ernst & Young, while the number of start ups founded balanced the number of companies liquidated (24 versus 25). However, the lack of private money could be largely compensated by state programmes such as the FSI-PME programme.  France also expanded its product pipeline. According to the report, 320 therapeutic products were in development whilst 20 were already being marketed in 2011. On top of that, diagnostic companies sold 59 in-vitro diagnostics and 21 in-vivo diagnostics. 

According to the report, the first foreign acquisitions by French companies took place in 2011. Swedish Cellartis AB was bought by Paris-based Cellectis S.A. and SC World Inc. from Japan by Vivalis SA (Nantes). In return, two French companies were acquired by foreign enterprises, namely Novagali Pharma S.A. (Évry) by Santen Pharmaceutical Co. Ltd. (Japan) and Ipsogen SA (Marseille) by Qiagen N.V. (Netherlands).


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)10.00 SEK14.29%
  • SERODUS (N)2.67 NOK9.43%


  • EVOCUTIS (UK)0.09 GBP-10.00%
  • VERONA PHARMA (UK)3.05 GBP-6.15%
  • SAREUM HOLDINGS (UK)0.19 GBP-5.00%


  • PLETHORA (UK)5.62 GBP80.1%
  • PROTHENA PLC (IE)73.19 USD46.1%
  • CELLECTIS (F)30.70 EUR32.8%


  • EPIGENOMICS (D)1.87 EUR-58.6%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)38.10 SEK5266.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)45.70 EUR255.9%


  • BIOTEST (D)15.34 EUR-81.0%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 25.11.2015